RxDoctor Payments Data

Glorifino Juan

Family · Merced, CANPI 1548997422

Payments from drug & device makers

$2,176in general payments, 2019–2025

Across 41 payments — averaging $53.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$540
  • Bayer$452
  • Novo Nordisk$274
  • Corcept Therapeutics$230
  • Amgen$196
  • GSK$162
  • plus $322 from 4 others

What the payments were for

  • Food & beverage$2,176100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,176 in reported general payments places this provider in the 85th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$4,652
Medicare patients
32
Services billed
52

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin59$47,848
OzempicSemaglutide25$21,205
JanuviaSitagliptin Phosphate17$20,120
TrulicityDulaglutide11$14,522
FarxigaDapagliflozin Propanediol16$9,952
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$2,972
Tresiba Flextouch U-100Insulin Degludec12$2,413
Albuterol Sulfate HfaAlbuterol Sulfate40$1,708
Atorvastatin Calcium150$1,444
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$1,395
LantusInsulin Glargine,hum.Rec.Anlog19$1,319
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic16$891
Gabapentin51$849
Omeprazole54$799
Levothyroxine Sodium47$556

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$274$21,20525 claims
Lilly USA, LLCTrulicity$62$14,52211 claims
AstraZenecaFarxiga$540$9,95216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,634 family providers in California.

Other family in Merced

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →